Dupilumab effectively induced remission of esophageal esophagitis (EoE) among children with eosinophilic esophagitis treated with the agent for atopic conditions, showed a recent study published in the Annals of Allergy, Asthma and Allergy. The researchers said that they analysed 45 patients at the Children’s Hospital of Philadelphia and Rady Children’s Hospital-San Diego who were prescribed dupilumab for asthma, atopic dermatitis or nasal polyps and who had concomitant EoE. The team wrote that thirty-nine of the patient cohort treated with dupilumab for an approved indication met the criteria for clinical improvement of their atopic condition. The research team concluded that ​​overall histology in the study fell from 52.9 eos/hpf at baseline to 4.5 eos/hpf after treatment.